Aeon Global Health Corp. Reports Earnings Results for the Third Quarter Ended March 31, 2019

Aeon Global Health Corp. is a healthcare company that offers a portfolio of solutions, which include laboratory diagnostic services. The Company offers a menu of healthcare services in cancer genomics, pharmacogenomics, toxicology, and infectious diseases. Its pharmacogenomics profile includes genetic-metabolic relationships for antifungal, antiemetic, acid disorder, immunosuppressant, and urinary incontinence medications. Its toxicology testing offers quantitative testing of drug metabolite levels in urine and oral fluids. Its testing covers over 80 analytes and metabolites (produced in the body after a drug has been taken). It has a lab-developed test validation for diagnostic testing used to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has the capacity to run approximately 2,000 Coronavirus Disease 2019 (COVID-19) tests per day. The Company serves, patients, shareholders, employees, and its communities.